145 related articles for article (PubMed ID: 23050928)
1. A combination of liposomal sunitinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse.
Maitani Y; Saito H; Seishi Y; Iwase Y; Yamauchi T; Higashiyama K; Sugino T
J Drug Target; 2012 Dec; 20(10):873-82. PubMed ID: 23050928
[TBL] [Abstract][Full Text] [Related]
2. Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer.
Di Desidero T; Antonelli A; Orlandi P; Ferrari SM; Fioravanti A; Alì G; Fontanini G; Basolo F; Francia G; Bocci G
Cancer Lett; 2017 Dec; 411():35-43. PubMed ID: 28964784
[TBL] [Abstract][Full Text] [Related]
3. Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation.
Li C; Cui J; Wang C; Li Y; Zhang L; Xiu X; Li Y; Wei N; Zhang L; Wang P
J Pharm Pharmacol; 2011 Jun; 63(6):765-73. PubMed ID: 21585373
[TBL] [Abstract][Full Text] [Related]
4. In Vitro and In Vivo Evaluation of Targeted Sunitinib-Loaded Polymer Microbubbles Against Proliferation of Renal Cell Carcinoma.
Hu J; Zong Y; Li J; Zhou X; Zhang J; Zhu T; Jiao M; Su H; Bo B
J Ultrasound Med; 2016 Mar; 35(3):589-97. PubMed ID: 26921089
[TBL] [Abstract][Full Text] [Related]
5. A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.
Boven E; Massard C; Armand JP; Tillier C; Hartog V; Brega NM; Countouriotis AM; Ruiz-Garcia A; Soria JC
Br J Cancer; 2010 Sep; 103(7):993-1000. PubMed ID: 20717111
[TBL] [Abstract][Full Text] [Related]
6. Dual functional octreotide-modified liposomal irinotecan leads to high therapeutic efficacy for medullary thyroid carcinoma xenografts.
Iwase Y; Maitani Y
Cancer Sci; 2012 Feb; 103(2):310-6. PubMed ID: 22017398
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan.
Riviere K; Kieler-Ferguson HM; Jerger K; Szoka FC
J Control Release; 2011 Aug; 153(3):288-96. PubMed ID: 21600250
[TBL] [Abstract][Full Text] [Related]
8. Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios.
Harasym TO; Tardi PG; Harasym NL; Harvie P; Johnstone SA; Mayer LD
Oncol Res; 2007; 16(8):361-74. PubMed ID: 17913044
[TBL] [Abstract][Full Text] [Related]
9. Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy.
Zhang B; Wang T; Yang S; Xiao Y; Song Y; Zhang N; Garg S
J Control Release; 2016 Sep; 238():10-21. PubMed ID: 27432750
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models.
Matsuzaki T; Takagi A; Furuta T; Ueno S; Kurita A; Nohara G; Kodaira H; Sawada S; Hashimoto S
Oncol Rep; 2012 Jan; 27(1):189-97. PubMed ID: 21935577
[TBL] [Abstract][Full Text] [Related]
11. Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model.
Denorme M; Yon L; Roux C; Gonzalez BJ; Baudin E; Anouar Y; Dubessy C
Cancer Lett; 2014 Oct; 352(2):236-44. PubMed ID: 25016061
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
13. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.
Kalra AV; Kim J; Klinz SG; Paz N; Cain J; Drummond DC; Nielsen UB; Fitzgerald JB
Cancer Res; 2014 Dec; 74(23):7003-13. PubMed ID: 25273092
[TBL] [Abstract][Full Text] [Related]
14. The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma.
Lopez-Barcons LA; Zhang J; Siriwitayawan G; Burke TG; Perez-Soler R
Neoplasia; 2004; 6(5):457-67. PubMed ID: 15548354
[TBL] [Abstract][Full Text] [Related]
15. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.
Messerer CL; Ramsay EC; Waterhouse D; Ng R; Simms EM; Harasym N; Tardi P; Mayer LD; Bally MB
Clin Cancer Res; 2004 Oct; 10(19):6638-49. PubMed ID: 15475454
[TBL] [Abstract][Full Text] [Related]
16. The influence of trapping agents on the antitumor efficacy of irinotecan liposomes: head-to-head comparison of ammonium sulfate, sulfobutylether-β-cyclodextrin and sucrose octasulfate.
Yang W; Yang Z; Fu J; Guo M; Sun B; Wei W; Liu D; Liu H
Biomater Sci; 2018 Dec; 7(1):419-428. PubMed ID: 30500018
[TBL] [Abstract][Full Text] [Related]
17. Activity of sunitinib in patients with advanced neuroendocrine tumors.
Kulke MH; Lenz HJ; Meropol NJ; Posey J; Ryan DP; Picus J; Bergsland E; Stuart K; Tye L; Huang X; Li JZ; Baum CM; Fuchs CS
J Clin Oncol; 2008 Jul; 26(20):3403-10. PubMed ID: 18612155
[TBL] [Abstract][Full Text] [Related]
18. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
Loi M; Marchiò S; Becherini P; Di Paolo D; Soster M; Curnis F; Brignole C; Pagnan G; Perri P; Caffa I; Longhi R; Nico B; Bussolino F; Gambini C; Ribatti D; Cilli M; Arap W; Pasqualini R; Allen TM; Corti A; Ponzoni M; Pastorino F
J Control Release; 2010 Jul; 145(1):66-73. PubMed ID: 20346382
[TBL] [Abstract][Full Text] [Related]
19. PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma.
Yang C; Liu HZ; Lu WD; Fu ZX
Oncol Rep; 2011 Jun; 25(6):1621-8. PubMed ID: 21455585
[TBL] [Abstract][Full Text] [Related]
20. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan.
Emerson DL; Bendele R; Brown E; Chiang S; Desjardins JP; Dihel LC; Gill SC; Hamilton M; LeRay JD; Moon-McDermott L; Moynihan K; Richardson FC; Tomkinson B; Luzzio MJ; Baccanari D
Clin Cancer Res; 2000 Jul; 6(7):2903-12. PubMed ID: 10914740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
